Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
163
resultados
Última actualización
02/08/2026 [07:30:00]
Resultados 100 a 125 de 163
Resumen de: WO2026130309A1
A potassium channel gene treatment method for treating Parkinson's disease. A recombinant adeno-associated virus (AAV) nucleotide sequence comprises a nucleotide sequence encoding an inwardly rectifying potassium channel Kir. An AAV vector is used to deliver an inwardly rectifying potassium channel (Kir) gene to the subthalamic nucleus, such that excitability of neurons of the subthalamic nucleus is reduced, so as to alleviate symptoms such as motor deficits caused by excessive excitation of the subthalamic nucleus in patients with Parkinson's disease.
Resumen de: WO2026136813A1
Disclosed herein is a polynucleotide comprising two or more siRNAs linked together with a single stranded nucleic acid. The two or more siRNAs may bind the same or bind different genes and may comprise a long passenger strand that is annealed to two or more guide strands with gaps of single stranded nucleic acids in between each duplex. Also disclosed herein a method of treating a disease or disorder comprising administering to a subject in need thereof a polynucleotide that targets genes associated with the disorder. The disease may include Alzheimer's disease.
Resumen de: US20260176633A1
Aspects of the disclosure relate to compositions and methods useful for treating Huntington's disease. In some embodiments, the disclosure provides interfering nucleic acids (e.g., artificial miRNAs) targeting the huntingtin gene (HTT) and methods of treating Huntington's disease using the same.
Resumen de: US20260174808A1
The present invention relates to a composition for preventing, ameliorating or treating cognitive dysfunction or Alzheimer's disease comprising, as an active ingredient, Lactobacillus fermentum SRK414 strain which has accession number KCTC13687BP. The strain of the present invention is excellent in reducing barrier permeability and reducing amyloid beta and tau proteins and has an excellent effect in improving cognitive function, and accordingly, the strain can be useful for a food and therapeutic agent for same purposes.
Resumen de: US20260174945A1
0000 Patients suffering from, or at risk of developing the symptoms of, Alzheimer's disease and related neuroinflammatory-based diseases, are treated by apheresis to selectively withdrawal Galectin-3 from the patient's body. A reduction in the circulating level of gal-3 of the patient of at least 30% of the patient's pre-treatment galectin-3 level should be sufficient to reduce AD symptoms, and/or inhibit AD progression. A greater withdrawal, up to at least 20%, has greater impact. Selective withdrawal of Galectin-3 may be coupled with the administration of MCP to further slow the progress of, and/or reverse, AD symptoms.
Resumen de: EP4763164A2
0001 The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.
Resumen de: EP4763972A1
0001 Provided are an Akkermansia muciniphila strain, and a product and a use thereof. The Akkermansia muciniphila strain is AKK PROBlO, and the preservation number thereof is CGMCC No. 20955, The AKK PROBIO has good tolerance, high safety, a wide range of indications and a good treatment effect, and can prevent and treat diseases such as colitis. colorectal cancer. Alzheimer's disease, and gouty arthritis.
Resumen de: EP4763834A2
The disclosure provide compounds of Formula Iand the pharmaceutically acceptable salts thereof. The variables, R1, R2, R3, X1, X2, and Z are defined herein. Certain compounds of Formula I act as selective mitochondrial protonophore uncouplers that do not affect the plasma membrane potential. Compounds and salts of Formula I are useful for treating or decreasing the risk of conditions responsive to mitochondrial uncoupling, such as cancer, obesity, type II diabetes, fatty liver disease, insulin resistance, Parkinson's disease, ischemia reperfusion injury, heart failure, non-alcoholic fatty liver disease (NALFD), and non-alcoholic steatohepatitis (NASH). Because mitochondrial uncouplers decrease the production of reactive oxygen species (ROS), which are known to contribute to age-related cell damage, compounds of Formula I are useful for increasing lifespan. Compounds and salts of Formula I are also useful for regulating glucose homeostasis or insulin action in a patient.
Resumen de: WO2025038863A1
Disclosed is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof. The variables in Formula (I) are defined herein. Compounds of Formula (I) are useful for regulating GPR17 activity and for treating disorders and diseases mediated by GPR17 in humans or non-humans.
Resumen de: WO2025038979A1
Material compositions and/or methods useful for the prophylaxis and/or treatment of protein depletion (proteinopenia) are provided, including material compositions that retains native function of a peptide/protein while limiting and/or preventing amyloid formation and/or aggregation of said peptide/protein. Material compositions and formulations for enhancing peptide/protein solubility, stability, circulation time, receptor interaction, brain penetrance, CSF half-life, facilitating peptide/protein synthesis and purification are also provided.
Resumen de: MX2026001933A
The present invention relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of cGAS, yet more in particular for the prevention or treatment of inflammation conditions or cancer. The present invention also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of cGAS, yet more in particular for the prevention or treatment of inflammation conditions or cancer. The present invention also relates to processes for the preparation of said compounds.
Resumen de: EP4763987A2
Provided herein are RNAi molecules for treating neurodegenerative synucleinopathies. In some embodiments, the RNAi molecules target expression of alpha-synuclein (SNCA). Further provided herein are expression constructs, vectors (e.g., rAAV), cells, viral particles, and pharmaceutical compositions containing the RNAi. Yet further provided herein are methods and kits related to the use of the RNAi, for example, to treat neurodegenerative synucleinopathies including Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies.
Resumen de: WO2021011673A2
Novel binding polypeptides (e.g., antibodies and antigen-binding fragments thereof) that specifically bind one or more species of soluble, AD brain-derived synaptotoxic amyloid beta (Aβ) without binding to classical monomeric, protofibrillar or fibrillar Aβ, are provided. Pharmaceutical compositions comprising binding polypeptides that specifically bind one or more species of soluble, synaptotoxic Aβ are provided. Methods of making binding polypeptides that specifically bind one or more species of soluble, synaptotoxic Aβ are provided. Methods of treating Alzheimer's disease using binding polypeptides that specifically bind one or more species of soluble, synaptotoxic Aβ are provided. Methods of reducing one or more symptoms of Alzheimer's disease using binding polypeptides that specifically bind one or more species of soluble, synaptotoxic Aβ are provided.
Resumen de: US20260166090A1
0000 The present disclosure provides methods of lineage specific differentiation of pluripotent stem cells, including induced pluripotent stem cells, into floor plate midbrain progenitor cells, determined dopamine (DA) neuron progenitor cells, and/or DA neurons. Also provided are compositions and uses thereof, such as for treating neurodegenerative diseases and conditions, including Parkinson's disease.
Resumen de: US20260167604A1
0000 Provided herein are compounds that inhibit HDAC6, a protein whose activity is associated with a variety of diseases (e.g., cancer, neurological disorders). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating HDAC6-related diseases and disorders (e.g., Alzheimer's disease, cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.
Resumen de: AU2026204322A1
The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may 5 be used to treat neurocognitive disorders (e.g., Alzheimer's disease, Parkinson's disease), ADHD, Epilepsy, Autism, Sleep-wake disorders, Chronic pain, Inflammatory Disorders, IBD, Stroke, ALS, and/or Multiple Sclerosis. un u n
Resumen de: US20260167941A1
The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease (PD) and Gaucher disease. In some embodiments, the disclosure provides expression constructs comprising a transgene encoding beta-Glucocerebrosidase (GBA) or a portion thereof alone or in combination with one or more PD-associated genes. In some embodiments, the disclosure provides methods of Parkinson's disease by administering such expression constructs to a subject in need thereof.
Resumen de: US20260165992A1
0000 Methods of treating central nervous system diseases with a combination of N-acetylcysteine and glucagon-like peptide-1 receptor agonist are disclosed. The methods include treatment of Parkinson's disease.
Resumen de: WO2026128848A1
The invention is a method for treating patients diagnosed with Parkinson's disease (PD), including post-encephalitic parkinsonism, parkinsonism that may follow carbon monoxide intoxication in adults, or parkinsonism that may follow manganese intoxication in adults by orally administering a controlled release muco-adhesive levodopa formulation and the method provides an improvement of a patient's total post-dose "Off" time compared to post-dose of treatment regimens with oral immediate release levodopa tablets administered with one or more COMT inhibitors, and/or FDA approved controlled release CD-LD product.
Resumen de: WO2026128833A1
In one aspect the present disclosure provides probiotic compositions having at least one gut bacterial species belonging to one or more genera selected from among Patescibacteria, Saccharimonadia, Saccharimonadales, Muribaculaceae, Saccharimonadaceae, Candidatus Saccharimonas, Lachnoclostridium, and Ruminococcus and methods for treating or preventing cognitive decline and Alzheimer's disease or improving cognitive performance in a subject in need thereof by administering said composition. In another aspect, the present disclosure provides method for treating or preventing Alzheimer's Disease or cognitive decline or improving cognitive function in a subject in need thereof comprising performing a fecal microbiota transplant (FMT) to the subject, wherein the FMT comprises at least one gut bacterial species belonging to one or more genera selected from among Patescibacteria, Saccharimonadia, Saccharimonadales, Muribaculaceae, Saccharimonadaceae, Candidatus Saccharimonas, Lachnoclostridium, and Ruminococcus.
Resumen de: US20260165993A1
Disclosed herein are methods of reducing α-synuclein (α-syn) misfolds or aggregates in the brain, and specifically, to methods of treating neurodegenerative disorders caused by α-synuclein (α-syn) in the brain, also referred to as α-synucleinopathies, and to methods of hindering or preventing α-synucleinopathy misfolds, and/or or to methods of proactively treating individuals at risk of α-synucleinopathy misfolds and associated disease. These α-synucleinopathies refer primarily to Parkinson's disease (PD), dementia with Lewy Bodies (DLB), and/or Multiple system atrophy (MSA). One embodiment includes a method of administering an L-tyrosine compound or derivative thereof to a subject in need thereof, (optionally in combination with an L-serine compound), and reducing the density and/or amount of α-synuclein aggregates in the brain of a mammal, thereby treating a mammal diagnosed with or suffering from or at risk of suffering from one or more α-synucleinopathies.
Resumen de: US20260166178A1
0000 The invention provides that the expression and/or activity of metal ion transporter, such as a Ca<2+>/Mn<2+> transporter and secretory pathway calcium ATPase 1 (SPCA1) or SPCA2 is associated with the restoration and conservation of Golgi integrity in cells, as well as with the restoration of Golgi ion concentrations. Provided herein are methods of restoring or maintaining Golgi integrity in a cell and methods of modulating Golgi ion concentration is a cell including increasing the expression and/or activity of a metal ion transporter such as SPCA1 or SPCA2 protein in the cell. The invention further provides methods of treating neurodegenerative disease, such as amyotrophic lateral sclerosis (ALS). The methods of treatment include increasing the expression and/or activity of a metal ion transporter such as SPCA1 or SPCA2 protein in cells to restore or maintain Golgi integrity and Golgi ion concentration in the cell.
Resumen de: US20260167636A1
The present invention relates to compounds which are suitable for imaging TDP-43 (Transactive response (TAR) DNA binding protein 43 kDa) aggregates. The compounds can be used, for example, for diagnosing a disease, disorder or abnormality associated with TDP-43 aggregates or a TDP-43 proteinopathy, such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Frontotemporal dementia (FTD) and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Nº publicación: AU2024383063A1 18/06/2026
Solicitante:
MERCK SHARP & DOHME LLC [US]
MERCK SHARP & DOHME LLC
Resumen de: AU2024383063A1
The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient, such as Alzheimer's Disease. Such methods entail administering a pharmaceutical composition comprising an immunogenic fragment of Aβ capable of inducing a beneficial immune response in the form of antibodies to Aβ. The immunogenic fragments comprise linear or multivalent peptides of Aβ. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant.
BOPI
Sede Electrónica
